Disc Medicine Appoints Lisa Amaya Price As Chief HR Officer To Support Hiring And Build a Scalable Organization Ahead Of Commercialization

Disc Medicine, Inc., a clinical-stage biopharmaceutical company advancing innovative treatments for serious hematologic diseases, announced the appointment of Lisa Amaya Price, MBA, as its new Chief Human Resources Officer. Ms. Amaya Price brings more than 25 years of experience in human resources and organizational leadership, including senior roles at several commercial-stage life science companies.

John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine, stated that the company is entering an important phase as it prepares for commercialization, which has led to a significant expansion in hiring. He noted that Ms. Amaya Price will play a critical role in building a strong and scalable organization by attracting, developing, and retaining top talent across all functions. He added that her leadership will help strengthen the company’s capabilities and support its long-term growth.

Ms. Amaya Price shared that she is excited to join Disc at a transformative time for the company. She emphasized that helping to build and scale a team while preparing to deliver a much-needed therapy to patients with unmet medical needs is both meaningful and motivating. She said she looks forward to collaborating across the organization to support its people and culture as the company enters its next stage of development.

Ms. Amaya Price joins Disc Medicine from Deciphera, where she served as Senior Vice President and Chief Human Resources Officer and helped lead the company’s integration into ONO Pharmaceuticals. Before that, she worked as Chief People Officer at LGC Group, a global life science tools company backed by private equity, employing more than 4,000 people worldwide. Her earlier leadership roles include serving as a senior HR executive at Scholar Rock and Takeda Pharmaceuticals, where she oversaw organizational design and talent selection during the acquisition of Shire Pharmaceuticals. 

She also spent eight years at Biogen in positions of increasing responsibility, most recently as Senior Director of Human Resources for R&D. Earlier in her career, she held HR leadership roles at Interpublic Group, Metro International S.A., and American Financial Systems, Inc. She holds a BA from Bard College, an MA from Simmons College, and an MBA from the F.W. Olin Graduate School of Business at Babson College.

In connection with her appointment, Disc Medicine granted Ms. Amaya Price an inducement equity award on January 12, 2026. The award includes an option to purchase 37,500 shares of common stock at the closing price on the grant date, a restricted stock unit (RSU) award for 25,000 shares, and an additional supplemental RSU award for 4,000 shares. The stock option vests 25% on January 12, 2027, with the remaining portion vesting in 36 equal monthly installments thereafter, subject to her continued service. 

The primary RSU award vests in four equal annual installments beginning February 15, 2026, and the supplemental RSU award vests in eight quarterly installments of 12.5% each, also beginning on February 15, 2026. The inducement award was approved by the Compensation Committee of the Board of Directors and granted under Nasdaq Listing Rule 5635(c)(4). While issued outside the company’s Amended and Restated 2021 Stock Option and Incentive Plan, the award terms are consistent with those of the existing plan.